Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 9, 2026, 10:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–4 of 4 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Palopegteriparatide Clear all
Recruiting Phase 3 Interventional

A Phase 3 Randomized Clinical Trial to Investigate the Safety and Efficacy of Palopegteriparatide at Doses Greater Than 30 μg/Day in Adult Participants With Hypoparathyroidism

NCT07081997
View directory record Official record
Conditions
Hypoparathyroidism, Endocrine System Diseases, Parathyroid Diseases
Interventions
Palopegteriparatide Experimental Arm, Palopegteriparatide Control Arm
Combination Product
Lead sponsor
Ascendis Pharma Bone Diseases A/S
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
7
States / cities
Chicago, Illinois • Minneota, Minnesota • Reno, Nevada + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2026 · Synced Sep 9, 2026, 10:23 AM EDT
Recruiting No phase listed Observational

A Study to Assess the Amount of Palopegteriparatide in Breast Milk of Lactating Females Requiring YORVIPATH® (Palopegteriparatide)

NCT07264634
View directory record Official record
Conditions
Hypoparathyroidism
Interventions
Palopegteriparatide
Drug
Lead sponsor
Ascendis Pharma A/S
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Sep 9, 2026, 10:23 AM EDT
Completed Phase 3 Interventional Results available

A Trial Investigating the Safety, Tolerability and Efficacy of TransCon PTH Administered Daily in Adults With Hypoparathyroidism

NCT04701203
View directory record Official record
Conditions
Hypoparathyroidism, Endocrine System Diseases, Parathyroid Diseases
Interventions
TransCon PTH, Placebo
Combination Product
Lead sponsor
Ascendis Pharma Bone Diseases A/S
Industry
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
9
States / cities
San Francisco, California • Chicago, Illinois • Rochester, Minnesota + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Sep 9, 2026, 10:23 AM EDT
Recruiting No phase listed Observational

A Global Pregnancy Registry to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to YORVIPATH® (Palopegteriparatide) During Pregnancy and Breastfeeding

NCT07345494
View directory record Official record
Conditions
Hypoparathyroidism
Interventions
Palopegteriparatide
Drug
Lead sponsor
Ascendis Pharma A/S
Industry
Eligibility
15 Years to 50 Years · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2036
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Mar 1, 2026 · Synced Sep 9, 2026, 10:23 AM EDT